Találati lista | Tudóstér

001-es BibID:	BIBFORM102567
035-os BibID:	(cikkazonosító)905585 (WoS)000827929000001 (Scopus)85133014637
Első szerző:	Kiss Zoltán
Cím:	Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study) / Zoltan Kiss, István Wittmann, Lórinc Polivka, György Surján, Orsolya Surján, Zsófia Barcza, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, János Szlávik, Zsuzsa Schaff, Zoltán Szekanecz, Cecília Müller, Miklós Kásler, Zoltán Vokó
Dátum:	2022
ISSN:	1664-3224
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk SARS-CoV2 infection boobster vaccine 4th vaccine omicron variant (SARS-Co-V2) delta variant (B.1.617.2) vaccine effectiveness mortalitiy
Megjelenés:	Frontiers in Immunology. - 13 (2022), p. 1-9. -
További szerzők:	Wittmann István Polivka Lőrinc Surján György Surján Orsolya Barcza Zsófia Molnár Gergő Attila Nagy Dávid Müller Veronika Bogos Krisztina Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Pálosi Mihály Szlávik János Schaff Zsuzsa Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Müller Cecília Kásler Miklós Vokó Zoltán (1968-) (epidemiológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM102494
035-os BibID:	(cikkazonosító)986 (WoS)000831789300001 (Scopus)85133021243
Első szerző:	Müller Veronika
Cím:	Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant / Veronika Müller, Lorinc Polivka, Istvan Valyi-Nagy, Alexandra Nagy, Zoltan Szekanecz, Krisztina Bogos, Hajnalka Vago, Anita Kamondi, Ferenc Fekete, Janos Szlavik, Jeno Elek, György Surján, Orsolya Surján, Péter Nagy, Zsuzsa Schaff, Cecília Müller, Zoltan Kiss, Miklós Kásler
Dátum:	2022
ISSN:	2076-393X
Megjegyzések:	Background: SARS-CoV-2 infections are associated with an increased risk of hospital admissions especially in the elderly (age >= 65 years) and people with multiple comorbid conditions. (2) Methods: We investigated the effect of additional booster vaccinations following the primary vaccination series of mRNA, inactivated whole virus, or vector vaccines on infections with the SARS-CoV-2 delta variant in the total Hungarian elderly population. The infection, hospital admission, and 28-day all-cause mortality of elderly population was assessed. (3) Results: A total of 1,984,176 people fulfilled the criteria of elderly including 299,216 unvaccinated individuals, while 1,037,069 had completed primary vaccination and 587,150 had obtained an additional booster. The primary vaccination series reduced the risk of infection by 48.88%, the risk of hospital admission by 71.55%, and mortality by 79.87%. The booster vaccination had an additional benefit, as the risk of infection, hospital admission, and all-cause mortality were even lower (82.95%; 92.71%; and 94.24%, respectively). Vaccinated patients needing hospitalization suffered significantly more comorbid conditions, indicating a more vulnerable population. (4) Conclusions: Our data confirmed that the primary vaccination series and especially the booster vaccination significantly reduced the risk of the SARS-CoV-2 delta-variant-associated hospital admission and 28-day all-cause mortality in the elderly despite significantly more severe comorbid conditions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk SARS-CoV-2 infection delta variant vaccine effectiveness mortality hospitalization elderly comorbidities
Megjelenés:	Vaccines. - 10 : 7 (2022), p. 1-9. -
További szerzők:	Polivka Lőrinc Vályi-Nagy István Nagy Alexandra Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Bogos Krisztina Vágó Hajnalka (1972-) (orvos) Kamondi Anita Fekete Ferenc Szlávik János Elek Jenő Surján György Surján Orsolya Nagy Péter (1976-) (vegyész) Schaff Zsuzsa Müller Cecília Kiss Zoltán Kásler Miklós
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM116830
035-os BibID:	(cikkazonosító)1786 (WoS)001131056200001 (Scopus)85180662724
Első szerző:	Polivka Lőrinc
Cím:	Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients : lessons from the Delta Variant / Lörinc Polivka, Istvan Valyi-Nagy, Zoltan Szekanecz, Krisztina Bogos, Hajnalka Vago, Anita Kamondi, Ferenc Fekete, Janos Szlavik, György Surjan, Orsolya Surjan, Peter Nagy, Zsuzsa Schaff, Zoltan Kiss, Cecilia Müller, Miklos Kasler, Veronika Müller
Dátum:	2023
ISSN:	2076-393X
Megjegyzések:	Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian COVID-19 registry was retrospectively investigated for risk of infection and hospitalization by time since the last vaccination, and vaccine effectiveness (VE) was calculated in adults with COPD diagnosis and an exact-matched control group during the Delta variant of concern (VOC) wave in Hungary (September-December 2021). For the matching, sex, age, major co-morbidities, vaccination status, and prior infection data were obtained on 23 August 2021. The study population included 373,962 cases divided into COPD patients (age: 66.67 +/- 12.66) and a 1:1 matched group (age: 66.73 +/- 12.67). In both groups, the female/male ratio was 52.2:47.7, respectively. Among the unvaccinated, there was no difference between groups in risk for infection or hospitalization. Regarding vaccinated cases, in the COPD group, a slightly faster decline in effectiveness was noted for hospitalization prevention, although in both groups, the vaccine lost its significant effect between 215 and 240 days after the last dose of vaccination. Based on a time-stratified multivariate Cox analysis of the vaccinated cases, the hazard was constantly higher in the COPD group, with an HR of 1.09 (95%: 1.05-1.14) for infection and 1.87 (95% CI: 1.59-2.19) for hospitalization. In our study, COPD patients displayed lower vaccine effectiveness against SARS-CoV-2 infection and hospitalization but a similar waning trajectory, as vaccines lost their preventive effect after 215 days. These data emphasize revaccination measures in the COPD patient population.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk COVID-19 COPD vaccine effectiveness VE waning
Megjelenés:	Vaccines. - 11 : 12 (2023), p. 1-12. -
További szerzők:	Vályi-Nagy István Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Bogos Krisztina Vágó Hajnalka (1972-) (orvos) Kamondi Anita Fekete Ferenc Szlávik János Surján György Surján Orsolya Nagy Péter Schaff Zsuzsa Kiss Zoltán Müller Cecília Kásler Miklós Müller Veronika
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103047
035-os BibID:	(cikkazonosító)919408 (WoS)000836947300001 (Scopus)85135452371
Első szerző:	Vokó Zoltán (epidemiológus)
Cím:	Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study) / Zoltán Vokó, Zoltán Kiss, György Surján, Orsolya Surján, Zsófia Barcza, István Wittmann, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Lőrinc Polivka, Mihály Pálosi, János Szlávik, György Rokszin, Cecília Müller, Zoltán Szekanecz, Miklós Kásler
Dátum:	2022
ISSN:	1664-3224
Megjegyzések:	Background: In late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in Hungary. Booster vaccines were offered for the vulnerable population starting from August 2021. Methods: The nationwide HUN-VE 3 study examined the effectiveness and durability of primary immunization and single booster vaccinations in the prevention of SARS-CoV-2 infection, Covid-19 related hospitalization and mortality during the Delta wave, compared to an unvaccinated control population without prior SARS-CoV-2 infection. Results: The study population included 8,087,988 individuals who were 18?100 years old at the beginning of the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14?120 days after primary immunization in the 16?64 and 65?100 years age cohort respectively, while it decreased to close to zero in the younger age group and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the population aged 65?100 years, we found high, 88.1%?92.5% adjusted effectiveness against Covid-19 infection after the Pfizer-BioNTech, and 92.2%?95.6% after the Moderna booster dose, while Sinopharm and Janssen booster doses provided 26.5%?75.3% and 72.9%?100.0% adjusted VE, respectively. Adjusted VE against Covid-19 related hospitalization was high within 14?120 days for Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less effective. VE against Covid-19 related death after primary immunization was high or moderate: for Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster. Conclusions: The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk booster vaccine delta variant vaccine effectiveness sinopharm sputnik-V janssen Covid-19
Megjelenés:	Frontiers in Immunology. - 13 (2022), p. 1-9. -
További szerzők:	Kiss Zoltán Surján György Surján Orsolya Barcza Zsófia Wittmann István Molnár Gergő Attila Nagy Dávid Müller Veronika Bogos Krisztina Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Polivka Lőrinc Pálosi Mihály Szlávik János Rokszin György Müller Cecília Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kásler Miklós
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: